The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation
Open accessAbstract
In vivo GITR ligation has previously been shown to augment T-cell-mediated anti-tumor immunity, yet the underlying mechanisms of this activity, particularly its in vivo effects on CD4+ foxp3+ regulatory T cells (Tregs), have not been fully elucidated. In order to translate this immunotherapeutic approach to the clinic it is important gain better understanding of its mechanism(s) of action. Utilizing the agonist anti-GITR monoclonal antibody DTA-1, we found that in vivo GITR ligation modulates regulatory T cells (Tregs) directly during induction of melanoma tumor immunity. As a monotherapy, DTA-1 induced regression of small established B16 melanoma tumors. Although DTA-1 did not alter systemic Treg frequencies nor abrogate the intrinsic suppressive activity of Tregs within the tumor-draining lymph node, intra-tumor Treg accumulation was significantly impaired. This resulted in a greater Teff:Treg ratio and enhanced tumor-specific CD8+ T-cell activity. The decreased intra-tumor Treg accumulation was due both to impaired infiltration, coupled with DTA-1-induced loss of foxp3 expression in intra-tumor Tregs. Histological analysis of B16 tumors grown in Foxp3-GFP mice showed that the majority of GFP+ cells had lost Foxp3 expression. These "unstable" Tregs were absent in IgG-treated tumors and in DTA-1 treated TDLN, demonstrating a tumor-specific effect. Impairment of Treg infiltration was lost if Tregs were GITR(-/-), and the protective effects of DTA-1 were reduced in reconstituted RAG1(-/-) mice if either the Treg or Teff subset were GITR-negative and absent if both were negative. Our results demonstrate that DTA-1 modulates both Teffs and Tregs during effective tumor treatment. The data suggest that DTA-1 prevents intra-tumor Treg accumulation by altering their stability, and as a result of the loss of foxp3 expression, may modify their intra-tumor suppressive capacity. These findings provide further support for the continued development of agonist anti-GITR mAbs as an immunotherapeutic strategy for cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Vignali, D. A. A., Collison, L. W., & Workman, C. J. (2008) · Nature Reviews Immunology · doi:10.1038/nri2343 · Cited by 3,463
Regulatory T Cell Lineage Specification by the Forkhead Transcription Factor Foxp3
Fontenot, J. D., Rasmussen, J. P., Williams, L. M., Dooley, J. L., Farr, A. G., & Rudensky, A. Y. (2005) · Immunity · doi:10.1016/j.immuni.2005.01.016 · Cited by 2,279
Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance
Shimizu, J., Yamazaki, S., Takahashi, T., Ishida, Y., & Sakaguchi, S. (2002) · Nature Immunology · doi:10.1038/ni759 · Cited by 1,729
Betts, M. R., Brenchley, J. M., Price, D. A., De Rosa, S. C., Douek, D. C., Roederer, M., & Koup, R. A. (2003) · Journal of Immunological Methods · doi:10.1016/s0022-1759(03)00265-5 · Cited by 1,587
CD4+CD25+ Immunoregulatory T Cells
McHugh, R. S., Whitters, M. J., Piccirillo, C. A., Young, D. A., Shevach, E. M., Collins, M., & Byrne, M. C. (2002) · Immunity · doi:10.1016/s1074-7613(02)00280-7 · Cited by 1,395
Zhou, X., Bailey-Bucktrout, S. L., Jeker, L. T., Penaranda, C., Martínez-Llordella, M., Ashby, M., Nakayama, M., Rosenthal, W., & Bluestone, J. A. (2009) · Nature Immunology · doi:10.1038/ni.1774 · Cited by 1,370
Foxp3-dependent programme of regulatory T-cell differentiation
Gavin, M. A., Rasmussen, J. P., Fontenot, J. D., Vasta, V., Manganiello, V. C., Beavo, J. A., & Rudensky, A. Y. (2007) · Nature · doi:10.1038/nature05543 · Cited by 1,135
Peggs, K. S., Quezada, S. A., Chambers, C. A., Korman, A. J., & Allison, J. P. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082492 · Cited by 967
Overwijk, W. W., Theoret, M. R., Finkelstein, S. E., Surman, D. R., de Jong, L. A., Vyth-Dreese, F. A., Dellemijn, T. A., Antony, P. A., Spiess, P. J., Palmer, D. C., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030590 · Cited by 925
Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression
Wan, Y. Y., & Flavell, R. A. (2007) · Nature · doi:10.1038/nature05479 · Cited by 854
Williams, L. M., & Rudensky, A. Y. (2007) · Nature Immunology · doi:10.1038/ni1437 · Cited by 853
Murai, M., Turovskaya, O., Kim, G., Madan, R., Karp, C. L., Cheroutre, H., & Kronenberg, M. (2009) · Nature Immunology · doi:10.1038/ni.1791 · Cited by 850
Quezada, S. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27745 · Cited by 700 · cited 1×
“A similar skewed ratio has recently been reported with an agonist anti-OX40 mAb, as well as antagonist anti-CTLA4 mAb, suggesting that an altered intra-tumor Teff:Treg ratio may be predictive of anti-tumor activity of these immune-modulating approaches[22,23,30,31].”
BackgroundHuehn, J., Siegmund, K., Lehmann, J. C. U., Siewert, C., Haubold, U., Feuerer, M., Debes, G. F., Lauber, J., Frey, O., Przybylski, G. K., et al. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031562 · Cited by 624
Epigenetic Regulation of Foxp3 Expression in Regulatory T Cells by DNA Methylation
Lal, G., Zhang, N., van der Touw, W., Ding, Y., Ju, W., Bottinger, E. P., Reid, S. P., Levy, D. E., & Bromberg, J. S. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.1.259 · Cited by 559
Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T Cells
Turk, M. J., Guevara-Patiño, J. A., Rizzuto, G. A., Engelhorn, M. E., & Houghton, A. N. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20041130 · Cited by 540
Self-citationKomatsu, N., Mariotti-Ferrandiz, M. E., Wang, Y., Malissen, B., Waldmann, H., & Hori, S. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811556106 · Cited by 523
Stephens, G. L., McHugh, R. S., Whitters, M. J., Young, D. A., Luxenberg, D., Carreno, B. M., Collins, M., & Shevach, E. M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.8.5008 · Cited by 499
Ko, K., Yamazaki, S., Nakamura, K., Nishioka, T., Hirota, K., Yamaguchi, T., Shimizu, J., Nomura, T., Chiba, T., & Sakaguchi, S. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.200509402092c · Cited by 462
Valzasina, B., Guiducci, C., Dislich, H., Killeen, N., Weinberg, A. D., & Colombo, M. P. (2005) · Blood · doi:10.1182/blood-2004-07-2959 · Cited by 428
OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection
Piconese, S., Valzasina, B., & Colombo, M. P. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071341 · Cited by 405
Ronchetti, S., Zollo, O., Bruscoli, S., Agostini, M., Bianchini, R., Nocentini, G., Ayroldi, E., & Riccardi, C. (2004) · European Journal of Immunology · doi:10.1002/eji.200324804 · Cited by 359
Regulatory T-cell compartmentalization and trafficking
Wei, S., Kryczek, I., & Zou, W. (2006) · Blood · doi:10.1182/blood-2006-01-0177 · Cited by 346
Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells
Tone, M., Tone, Y., Adams, E., Yates, S. F., Frewin, M. R., Cobbold, S. P., & Waldmann, H. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2334901100 · Cited by 345
Speed congenics: a classic technique in the fast lane (relatively speaking)
Wakeland, E., Morel, L., Achey, K., Yui, M., & Longmate, J. (1997) · Immunology Today · doi:10.1016/s0167-5699(97)01126-2 · Cited by 333
Plasticity of CD4+ FoxP3+ T cells
Zhou, X., Bailey-Bucktrout, S., Jeker, L. T., & Bluestone, J. A. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.05.007 · Cited by 317
Functional Impairment of CD8+ T Cells by Regulatory T Cells during Persistent Retroviral Infection
Dittmer, U., He, H., Messer, R. J., Schimmer, S., Olbrich, A. R. M., Ohlen, C., Greenberg, P. D., Stromnes, I. M., Iwashiro, M., Sakaguchi, S., et al. (2004) · Immunity · doi:10.1016/s1074-7613(04)00054-8 · Cited by 316
Kanamaru, F., Youngnak, P., Hashiguchi, M., Nishioka, T., Takahashi, T., Sakaguchi, S., Ishikawa, I., & Azuma, M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.12.7306 · Cited by 285
Migration matters: regulatory T-cell compartmentalization determines suppressive activity in vivo
Siegmund, K., Feuerer, M., Siewert, C., Ghani, S., Haubold, U., Dankof, A., Krenn, V., Schön, M. P., Scheffold, A., Lowe, J. B., et al. (2005) · Blood · doi:10.1182/blood-2005-05-1864 · Cited by 246
Agonist Anti-GITR Antibody Enhances Vaccine-Induced CD8+ T-Cell Responses and Tumor Immunity
Cohen, A. D., Diab, A., Perales, M.-A., Wolchok, J. D., Rizzuto, G., Merghoub, T., Huggins, D., Liu, C., Turk, M. J., Restifo, N. P., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2813 · Cited by 202
Self-citationHara, I., Takechi, Y., & Houghton, A. N. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.5.1609 · Cited by 184
Self-citationNocentini, G., & Riccardi, C. (2005) · European Journal of Immunology · doi:10.1002/eji.200425818 · Cited by 179
OX40 Agonist Therapy Enhances CD8 Infiltration and Decreases Immune Suppression in the Tumor
Gough, M. J., Ruby, C. E., Redmond, W. L., Dhungel, B., Brown, A., & Weinberg, A. D. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6484 · Cited by 174
Ramirez-Montagut, T., Chow, A., Hirschhorn-Cymerman, D., Terwey, T. H., Kochman, A. A., Lu, S., Miles, R. C., Sakaguchi, S., Houghton, A. N., & van den Brink, M. R. M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.11.6434 · Cited by 173
Self-citationRole of GITR in activation response of T lymphocytes
Ronchetti, S., Nocentini, G., Riccardi, C., & Pandolfi, P. P. (2002) · Blood · doi:10.1182/blood-2001-12-0276 · Cited by 165
Kohm, A. P., Williams, J. S., & Miller, S. D. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.8.4686 · Cited by 152
Zhou, P., L’Italien, L., Hodges, D., & Schebye, X. M. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.11.7365 · Cited by 109
Muriglan, S. J., Ramirez‐Montagut, T., Alpdoğan, Ö., van Huystee, T., Eng, J. M., Hubbard, V. M., Kochman, A. A., Tjoe, K. H., Riccardi, C., Pandolfi, P. P., et al. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040116 · Cited by 103
Self-citationNishikawa, H., Kato, T., Hirayama, M., Orito, Y., Sato, E., Harada, N., Gnjatic, S., Old, L. J., & Shiku, H. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5839 · Cited by 88
Esparza, E. M., & Arch, R. H. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.7869 · Cited by 81
Suvas, S., Kim, B., Sarangi, P. P., Tone, M., Waldmann, H., & Rouse, B. T. (2005) · Journal of Virology · doi:10.1128/jvi.79.18.11935-11942.2005 · Cited by 68
高, 貴. (2006) · Medical Entomology and Zoology · Cited by 68
Migration and function of FoxP3+ regulatory T cells in the hematolymphoid system
Kim, C. H. (2006) · Experimental Hematology · doi:10.1016/j.exphem.2006.03.014 · Cited by 56
Zhou, Z., Song, X., Berezov, A., Zhang, G., Li, Y., Zhang, H., Murali, R., Li, B., & Greene, M. I. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711350105 · Cited by 51
Self-citationSpecific recruitment of regulatory T cells into the CSF in lymphomatous and carcinomatous meningitis
Haas, J., Schopp, L., Storch-Hagenlocher, B., Fritzsching, B., Jacobi, C., Milkova, L., Fritz, B., Schwarz, A., Suri‐Payer, E., Hensel, M., et al. (2007) · Blood · doi:10.1182/blood-2007-08-104877 · Cited by 47
Kim, H. J., Kim, H. Y., Kim, B. K., Kim, S., & Chung, D. H. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.6.3507 · Cited by 46
Self-citationSuri, A., Shimizu, J., Katz, J. D., Sakaguchi, S., Unanue, E. R., & Kanagawa, O. (2004) · European Journal of Immunology · doi:10.1002/eji.200324599 · Cited by 27
Functional Impairment of CD8 T Cells by Regulatory T Cells during Persistent Retroviral Infection
Dittmer, U., & Hasenkrug, K. J. (2004) · Immunity · doi:10.1016/s1074-7613(04)00115-3 · Cited by 19
Cited by
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Combination cancer immunotherapy and new immunomodulatory targets
Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4591 · Cited by 1,294
Cancer immunotherapy: the beginning of the end of cancer?
Farkona, S., Diamandis, E. P., & Blasutig, I. M. (2016) · BMC Medicine · doi:10.1186/s12916-016-0623-5 · Cited by 1,184
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Khalil, D. N., Smith, E. L., Brentjens, R. J., & Wolchok, J. D. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.25 · Cited by 929
Self-citationT-Regulatory Cells: Key Players in Tumor Immune Escape and Angiogenesis
Facciabene, A., Motz, G. T., & Coukos, G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3687 · Cited by 821
Metadata
- Authors
- Cohen, A. D., Schaer, D. A., Liu, C., Li, Y., Hirschhorn-Cymmerman, D., Kim, S. C., Diab, A., Rizzuto, G., Duan, F., Perales, M. A., Merghoub, T., Houghton, A. N., & Wolchok, J. D.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-05-03
- Volume
- 5
- Issue
- 5
- Pages
- e10436
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2134435470
- Cited by
- 261
- References
- 49
- FWCI
- 7.26
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.